Oculis Holding AG (OCS) Other Working Capital Changes (2023 - 2026)
Oculis Holding AG's (OCS) quarterly Other Working Capital Changes came in at -$1277.0 in Q1 2026, up 96.41% year-on-year from -$650.17 in Q1 2025, and down 151.08% quarter-over-quarter from $2500.2 in Q3 2025.
Oculis Holding AG (OCS) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Oculis Holding AG's Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$1277.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes rose 96.41% year-over-year to -$1277.0 in Q1 2026; TTM through Mar 2026 was -$62150.3, a 99.59% decrease from a year earlier, with the FY2024 full-year figure at -$107986.6, down 234.43% from the prior year.
- Other Working Capital Changes eased to -$1277.0 in Q1 2026 per OCS's latest filing, from $2500.2 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $4.7 million in Q1 2024 and bottomed at -$6.9 million in Q4 2024.
- The 5-year median for Other Working Capital Changes is $101629.3 (2023), against an average of -$110616.1.
- Across the five-year window, Other Working Capital Changes tumbled 150.63% in 2024 and soared 96.41% in 2026, its largest moves.
- Year by year, Other Working Capital Changes stood at $9018.8 in 2023, then tumbled by 150.63% to -$4566.1 in 2024, then jumped by 154.76% to $2500.2 in 2025, then sank by 151.08% to -$1277.0 in 2026.
- Per Business Quant, the three latest OCS Other Working Capital Changes figures stand at -$1277.0 (Q1 2026), $2500.2 (Q3 2025), and -$27781.5 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,277.00 |
| Mar 31, 2026 | -1,277.00 |
| Mar 31, 2026 | -1,277.00 |
| Sep 30, 2025 | 2,500.22 |
| Sep 30, 2025 | 2,500.22 |
| Sep 30, 2025 | 2,500.22 |
| Jun 30, 2025 | -27,781.48 |
| Jun 30, 2025 | -27,781.48 |
| Jun 30, 2025 | -27,781.48 |
| Mar 31, 2025 | -35,592.02 |
| Mar 31, 2025 | -35,592.02 |
| Mar 31, 2025 | -35,592.02 |
| Dec 31, 2024 | -4,566.09 |
| Dec 31, 2024 | -4,566.09 |
| Dec 31, 2024 | -4,566.09 |
| Dec 31, 2023 | 9,018.84 |
| Dec 31, 2023 | 9,018.84 |
| Dec 31, 2023 | 9,018.84 |
| Sep 30, 2023 | -3,396.46 |
| Sep 30, 2023 | -3,396.46 |